Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for Relapse Prevention in Severe Aplastic Anemia
NCT02979873Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2016
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in aplastic anemia comparing Sirolimus with Observation (2 arms). Primary endpoint: Rate of Relapse at 24 months. Started Dec 2016; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT02979873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979873.